Summary of data confirmations through interlaboratory analysis

Summary of data confirmations through interlaboratory analysis

Dear friends, 

We start this report in a different way, more emotional being the last of 2019 and having reached the end of what is planned for this year. It is a summary document of the work carried out containing only the confirmations of the data that were initially probable and that have now become certain.

We have run out of funds for this project and we are still satisfied because having empty accounts in this period of struggle means that we have used all the energy for the battle, without sparing us.

As happened since 2017 there we will self-finance thanks to membership fees and donations from us parents and we will proceed in 2020 with a whole series of investigations that should take the matter to a higher level but, in the meantime, we will devote the next few months to inform and interact with foreign associations for proceed with the international complaint. We have a lot of work, honestly there are more ideas than the energies and economic possibilities available.

Together we embarked on a path that has lasted a long time, and today we have managed to make the results of this project known to the whole world. The determination of us parents and Italian citizens is an example today for many other countries which unfortunately are preparing to fight the same battles in defense of fundamental human rights.

Yes, it is very true, the institutions appear deaf and a comma has not yet moved, at least not in an obvious way and, more distressing, our children are excluded from schools, but let's look around: the world system gravitates around the vaccination dogma supported by a "scientific community" which, only in Italy, has received more than half a billion euros in a few years. 1 It is a real rain of money that has moved a host of pseudo-scientists, hired doctors and ignorant politicians, ready to protect the interests of those organisms that Prof. Randy Schekman, Nobel Prize in Medicine in 2013, called " caste". 2

"Science is at risk: it is no longer reliable because it is in the hands of a closed and far from independent caste" and this is now evident even to the most skeptical of spectators - if in good faith. It pursues interests that are not those which accompany the scientific method, at least not as it should be; it produces studies which, in order to be published, must respect some imposed dogmas, omitting some data that "do not agree" or highlighting others that "are convenient" and this we have experienced on our skin, even though we have only faced this world.

In this despicable situation, we found ourselves having to face an imposition of law for the administration of pharmaceutical products, a law that inevitably enriches and increases the power of that caste mentioned by the nobel Schekman.

Faced with such a socio-political situation, we strengthened, we citizens and parents aware and determined, with the help of other citizens like us we took those actions that seemed more effective or simply more "affordable" based on the possibilities we had: we have shown that with few forces, but with determination, great results can be produced.

We started with these few opening lines because today, as the latest Corvelva report, we will talk about the latest results, which are confirmations that have come from analyzes carried out both by a prestigious European university and by other certified laboratories located in different parts of the world. The data are more and more certain and what was previously probable is now DEMONSTRATED!

Among other things, we have investigated a number of toxic and / or carcinogenic compounds such as nitrosodimethylamine NDMA and cyanhydrins and the results have been truly worrying. We will compulsorily discuss this with peer review publications in order not to compromise the publications themselves.

As explained, even these insights, such as those of fetal DNA sequencing, are the subject of the next publication in peer review, therefore we are really communicating a minimal part of what will be published, but so science asks, that the data is unpublished. By reporting more details, we will put the work done. However, the fact remains that the control bodies have received everything, in original!

We will proceed with the information and fight so that the shocking results are considered for what they are, pure analytical data without preconceptions or ideologies. Those products analyzed by us are to be collected en masse and there is a great question to be asked about the interests that gravitate around all those who have come up against our analyzes and / or in favor of the vaccination dogma.

Together we can try to stop all this madness.

Summary of the results obtained and confirmed for each vaccine

To carry out this investigation, it was decided to use a cut-off between the nanograms and micrograms, therefore above the residual limit for compounds not known and not reported in the technical data sheet.

It should be emphasized that the cumulative amount of these contaminants is above micrograms per dose, although it is not currently possible to make an exact quantification, since most of the contaminants are unknown and therefore it is not possible to carry out the study by means of analytical control standards.

From the results of the screening and controls with the standards, it appears that the metabolic fraction has candidate compounds that can be explained only with poor control, and consequently with the poor quality, raw materials and reagents. In particular, cross-contamination with chemical compounds with known pharmacological activity is out of control, although it is possible that the production process of the vaccine changes its original structure and conformation.  

corvelva summary analysis1

Specify confirmed results

At the bottom of this summary we will report all the links of all the reports of the analyzes performed, always refer to them for a detailed understanding of the results, since below we will only talk about the confirmatory analyzes by means of second level screening, control standards and / or interlaboratory.

An example to better understand: a certified service provider performed some analyzes on our request. They were asked to target, identify the presence or absence of certain organic or inorganic compounds in certain (not all) vaccines or genetic sequences. The result is therefore only on what we asked to look for, an indispensable element to confirm the validity of the method we use. 

The reasons for not having used numerous control standards and other commercially available vaccines has economic and logical roots: we are not a research body and we are carrying out in-depth analyzes, after reporting non-compliance with regulatory bodies, which go beyond what we do should compete; to all intents and purposes we are improperly substituting the regulatory bodies themselves in investigations that would be up to them after a report of this magnitude, and we are doing it because our data have been defined incomplete.

Hexyon vaccine analysis


The presence of the contaminating genetic material was confirmed with interlaboratory analysis at a certified European service provider.

The DNA present is equal to 6,88 ng total per dose (this quantity refers to the report disclosed. The data of the interlaboratory analysis is subject to peer review and therefore not disclosed but confirms the order of magnitude), of which 0,1 , 688% potentially from Vero (Cercopithecidae) cells, i.e. XNUMX pg / dose. We have identified Clostridium phage phiCT453A and SV40 together with other vectors for cloning.

Presence of Poliovirus 1 and 2. In this case, the response of the EMA to the absence of Poliovirus 3 was very generic, the absence is not a non-compliance for them since they give for granted the presence of the D antigen, capable of creating immunization. Obviously we have looked for this protein but we have not been able to find it, it would be an excellent study to be developed because we currently leave an uncertain answer on this point.

DNA and RNA of the bacteria used for the production of the antigens of Corynebacterium diphtheriae (Diphtheria), Clostridium tetani (Tetanus), Bordetella pertussis (Pertussis) and Haemophilus influenzae.

NOTE: the adventitious genetic material present in the vaccine can be linked to the adjuvant aluminum with possible enhancement of the toxic effects (inflammatory, autoimmune and tumor capacity). We reiterate that, from the confirmed interlaboratory data, the safety and efficacy of this vaccine remains dubious, resulting in a completely non-compliant product with regard to quality.

Gardasil 9 vaccine analysis


After the previous results, we decided to deepen the identification, with interlaboratory confirmation, of the compound APDB (illegal amphetamine) already notified to the NAS on May 23, 2019. Two different laboratories confirm the presence of a substance belonging to the class of illegal APDB.

We, we repeat, cannot buy the control standard being theAPDB classified as amazing, 3 it cannot be acquired by subjects without specific authorization, therefore we have provided all the documentation confirming the presence of a substance belonging to the APDB class and the possible origin of the contamination (Note: It is reported in the EMA assessment report for registration of Gardasil 9 that L-tyrosine is used as a raw material for the production of this vaccine and is extracted from human hair from China. 4 The main production of this narcotic comes from China and drug addicts have a very high level in the hair. 5


The presence of the genetic material was confirmed with interlaboratory analysis at a certified European service provider and we can repeat the previous data, there are:

  • Human and mouse DNA (under the detection limits of the instrument)
  • Adventitious viruses: 
    • L1 fragment of the HPV virus of double-chain DNA;
    • Phages;
    • Molluscum contagiosum virus;
  • Retroviruses: 
    • Murine leukemia virus; 
    • Human endogenous retrovirus K.
    • saccharomyces

NOTE: the adventitious genetic material present in the vaccine can be linked to the adjuvant aluminum with possible enhancement of toxic effects (inflammatory, autoimmune and tumor capacity)

Priorix Tetra vaccine analysis


The presence of the genetic material was confirmed with interlaboratory analysis at a certified European service provider. The quantities refer to the reports disclosed. The data of the interlaboratory analysis are subject to peer review and therefore not disclosed but confirm the order of magnitude

DNA - The amount of total DNA present in this vaccine ranges from: 1.7 - 3.7? G / dose and is in all respects the main component of the vaccine. DNA is about 80% human (74-88%) and chicken (0-4%).

The human genome is complete, that is, with non-coding, high molecular weight, male genes and sequences, qualified as belonging to the MRC-5 fetal line, that is, the continuous cell line derived from lung tissue of a male abortion fetus of the 60s. The sequencing of this cell line has proven how was highly modified from a genetic and potentially carcinogenic point of view. The whole genome sequencing analysis of fetal DNA was performed by an American service provider (laboratory).

RNA - Human 68-87%. Chicken 0-0.2%

Attenuated viruses - The following attenuated viruses have been confirmed lot. A71CB256A:

  • Chickenpox (DNA) 11%; 
  • Mumps (RNA) 0.008%;
  • Measles (RNA) 0.004%; 
  • Rubella 0.00004%. (114 out of 260 million sequences)

An irrelevant presence of rubella in the vaccine (lower than the adventitious viruses indicated below) was confirmed interlaboratory. This seriously questions the effectiveness of the vaccine.

Viral quasi-species: 245 variants have been identified in the vaccine chickenpox genome compared to the reference genome used for the analysis (wild genome of the Dumas strain). Of these variants, 154 are major variants while the rest 91 are quasi-species variants. No difference emerges from the comparison between the variants found in the two lots. In the mumps vaccine genome, 40 quasi-species variants were identified with respect to the reference genome used for the analysis (Jeryl-Lynn vaccine genome). 4 differences emerge from the comparison between the variants found in the two lots. The EMA was unable to provide us with the vaccine virus sequences used by the manufacturer for this vaccine, as they are covered by industrial secrecy, which is why we do not know how much the vaccine viruses have changed compared to what was declared by the manufacturer

Due to the low coverage it was not possible to detect quasi-species variants for the measles and rubella genomes.

Adventitious viruses - We confirmed the presence of these adventitious viruses:

  • Human endogenous retrovirus K;
  • Avian leukosis virus; 
  • HERV-H / env62.

For all vaccines

Analysis with control and interlaboratory standards on chemical contaminations

Two compounds were chosen to be analyzed with certified control standards, based on the availability, the consistency of the semi-quantitative data and the impact on health. These compounds have been confirmed as similar (i.e. with a structural identity of 75-80%: isomers / isobars) also through inter-laboratory analysis. The structure of these compounds will be disclosed in the peer review publication.

Second level screening on chemical contaminations

The second level screening investigation, as already mentioned, is divided into three analyzes:

  • in-depth screening of the submerged part (65% of the total of the signals) and comparison in the database of the detected substances, including the database of toxins.
  • neutral loss analysis: the detection of neutral stable fragmentation allows us to hypothesize the presence in the vaccine of molecules that contain them, of unknown structure, but with potential toxic effects if the functional groups have carcinogenic and mutagenic activity (the "Cohort of concern" created by the EMA for oral medications includes aflatoxin-like, N-nitroso- and alkyl-azoxy compounds, as reported in the ICH guideline M7 (R1). 6

New Candidate Compounds: Potentially toxic compounds (cross-contamination) were identified for all vaccines tested based on comparison with databases. It would be useful to deepen through control standards to confirm their identity.

Neutral losses: In our case, the cyanyl groups (i.e. derived from hydrogen cyanide used for the preparation of the Haemophilus B vaccine) and nitrosodimethylamine, a carcinogenic impurity found in other drugs and subject to evaluation by the EMA, were examined. 7

To understand the functional group of nitrosodimethylamine, think that it is of the same class as the contaminations found in the drugs sartani and ranitidine, which has jumped to the headlines for the recent massive withdrawal of drugs throughout Europe. 8 The second functional group is that of cyanides, of which we know the declared presence of sodium cyanide as shown in the technical data sheets of the Prevenar vaccine. 9

Second level screening therefore gave a positive response for all vaccines. At the moment it is not possible to disclose the results in detail because during the publication of the peer review, but all regulatory bodies have been made aware of our results.

The legislation

Please note what must be done by law on the drugs on the market: 10

The Annual Control Program makes it possible to guarantee that the drugs marketed correspond exactly to the quality specifications of the authorization procedures. It is established every year by AIFA, after hearing the opinion of the Istituto Superiore della Sanità, and is approved by the AIFA Scientific Technical Commission (CTS). The AIFA Product Quality Office requires the NAS carabinieri to take samples of the medicines included in the program from pharmacies or wholesalers, which are sent to the ISS for analysis. If the results of the analysis reveal any discrepancies from what is authorized, the AIFA Product Quality Office takes the necessary measures. The analyzes carried out are based on the verification of compliance with the quality specifications authorized for each drug and reported in the registration dossier and / or in the European Pharmacopoeia monographs. (...)

The Product Quality Office also manages the ex officio withdrawal and suspension of marketing authorizations for medicinal products.

The marketing authorization of a medicinal product can be revoked, with consequent definitive withdrawal from the market when:

  1. the medicine is harmful in normal conditions of use;
  2. the medicinal product does not have the therapeutic effect or the effect for which it was authorized;
  3. the risk / benefit ratio is not favorable in normal conditions of use;
  4. the medicinal product does not have the declared qualitative and quantitative composition;
  5. the medicine was produced in unauthorized factories.

The authorization can also be revoked if it is found that the information present in the application for authorization of the medicinal product is incorrect or in the absence of checks on the finished product, on the components or on the intermediate products of the production.

In addition to the interventions adopted at national level, the measures of the Rapid Alert System, defined on the basis of shared procedures at European level, which provides for different actions and notifications in relation to the type of seriousness of the defect in accordance with the classification of emergencies are simultaneously carried out .

Figure 2 describes the classification of defects and the related actions to be taken

It should be noted that i defects detected with the analyzes carried out by Corvelva fall into Class I and II, as the vaccines are injective drugs and the detected contaminations are chemical and genetic.

It is emphasized that to date no measures have been taken by regulatory agenciesdespite notifying AIFA of the results of the preliminary analyzes and the NAS of the presence of the APDB compound in the Gardasil 9 vaccine, and this is in serious violation of the precautionary principle and the need for rapid intervention as envisaged by the Alert System for the protection of public health.

Download: CORVELVA-Summary-confirmations-data-analysis-interlaboratorio.pdf


  5. Gas Chromatography-Mass Spectrometry (GC-MS) AnalysisJournal of Food and Drug Analysis, Vol. 13, No. 3, 2005, Pages 193-200 Gas Chromatography-Mass Spectrometry (GC-MS) Analysis of Amphetamine, Methamphetamine, 3,4-Methylenedioxy- amphetamine and 3,4-Methylenedioxymethamphetamine in Human Hair and Hair SectionsDONG-LIANG LIN1,2 *, REA-MING YIN1 AND RAY H. LIU3
  6. … /ich-guideline-m7r1-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit_en.pdf
  8. … /news/non_solo_ranitidina_per_l_ema_vanno_testati_tutti_i_farmaci_per_impurita_cancerogene-237010173/

Publish the Menu module to "offcanvas" position. Here you can publish other modules as well.
Learn more.